Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Stuart Jay Schnitt, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Stuart Schnitt and Laura Collins.
Stuart Schnitt
Connection Strength
6.997
Laura Collins
  1. Papillary lesions of the breast: selected diagnostic and management issues. Histopathology. 2008 Jan; 52(1):20-9.
    View in: PubMed
    Score: 0.371
  2. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study. Cancer. 2007 Jan 15; 109(2):180-7.
    View in: PubMed
    Score: 0.347
  3. The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study. Cancer. 2006 Sep 15; 107(6):1240-7.
    View in: PubMed
    Score: 0.339
  4. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers. Am J Surg Pathol. 2006 Aug; 30(8):1002-7.
    View in: PubMed
    Score: 0.336
  5. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Mod Pathol. 2005 May; 18(5):615-20.
    View in: PubMed
    Score: 0.308
  6. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer. 2005 May 01; 103(9):1778-84.
    View in: PubMed
    Score: 0.308
  7. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol. 2005 Jan; 123(1):16-20.
    View in: PubMed
    Score: 0.301
  8. Diagnostic agreement in the evaluation of image-guided breast core needle biopsies: results from a randomized clinical trial. Am J Surg Pathol. 2004 Jan; 28(1):126-31.
    View in: PubMed
    Score: 0.281
  9. Mucin Neovascularization as a Diagnostic Aid to Distinguish Mucinous Carcinomas From Mucocele-like Lesions in Breast Core Needle Biopsies. Am J Surg Pathol. 2021 Sep 21.
    View in: PubMed
    Score: 0.240
  10. The impact of mammographic screening on the subsequent breast cancer risk associated with biopsy-proven benign breast disease. NPJ Breast Cancer. 2021 Mar 05; 7(1):23.
    View in: PubMed
    Score: 0.231
  11. Benign breast lesions that mimic malignancy. Pathology. 2017 Feb; 49(2):181-196.
    View in: PubMed
    Score: 0.173
  12. Reply to breast cancer risk by the extent and type of atypical hyperplasia. Cancer. 2016 10; 122(19):3088-9.
    View in: PubMed
    Score: 0.167
  13. Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. NPJ Breast Cancer. 2016; 2:16002.
    View in: PubMed
    Score: 0.163
  14. Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses' Health Studies. Cancer. 2016 Feb 15; 122(4):515-20.
    View in: PubMed
    Score: 0.160
  15. Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case-Control Study. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S502-8.
    View in: PubMed
    Score: 0.155
  16. Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat. 2013 Jun; 139(2):453-60.
    View in: PubMed
    Score: 0.134
  17. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012 Jan; 131(1):159-67.
    View in: PubMed
    Score: 0.119
  18. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol. 2011 Jul; 24(7):924-31.
    View in: PubMed
    Score: 0.117
  19. Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast Cancer Res Treat. 2011 Jul; 128(1):243-50.
    View in: PubMed
    Score: 0.114
  20. Phenotypic alterations in myoepithelial cells associated with benign sclerosing lesions of the breast. Am J Surg Pathol. 2010 Jun; 34(6):896-900.
    View in: PubMed
    Score: 0.110
  21. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res. 2010; 12(1):R12.
    View in: PubMed
    Score: 0.107
  22. Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol. 2009 Dec; 33(12):1802-8.
    View in: PubMed
    Score: 0.106
  23. Potential role of tissue microarrays for the study of biomarker expression in benign breast disease and normal breast tissue. Appl Immunohistochem Mol Morphol. 2009 Oct; 17(5):438-41.
    View in: PubMed
    Score: 0.105
  24. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol. 2009 Jul; 33(7):1093-7.
    View in: PubMed
    Score: 0.103
  25. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications. Am J Surg Pathol. 2009 Feb; 33(2):227-32.
    View in: PubMed
    Score: 0.100
  26. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 2008; 10(4):R67.
    View in: PubMed
    Score: 0.097
  27. Clinical and pathologic features of ductal carcinoma in situ associated with the presence of flat epithelial atypia: an analysis of 543 patients. Mod Pathol. 2007 Nov; 20(11):1149-55.
    View in: PubMed
    Score: 0.091
  28. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. 2006 May; 19(5):617-21.
    View in: PubMed
    Score: 0.083
  29. Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast. Mod Pathol. 2006 Feb; 19(2):172-9.
    View in: PubMed
    Score: 0.081
  30. TDLU Involution and Breast Cancer Risk-Reply. Cancer Epidemiol Biomarkers Prev. 2021 04; 30(4):798.
    View in: PubMed
    Score: 0.058
  31. Deep Learning Image Analysis of Benign Breast Disease to Identify Subsequent Risk of Breast Cancer. JNCI Cancer Spectr. 2021 02; 5(1).
    View in: PubMed
    Score: 0.057
  32. Testosterone therapy and breast histopathological features in transgender individuals. Mod Pathol. 2021 01; 34(1):85-94.
    View in: PubMed
    Score: 0.056
  33. Automated Quantitative Measures of Terminal Duct Lobular Unit Involution and Breast Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020 11; 29(11):2358-2368.
    View in: PubMed
    Score: 0.056
  34. Retinoblastoma protein expression and its predictors in triple-negative breast cancer. NPJ Breast Cancer. 2020 Jun 05; 6(1):19.
    View in: PubMed
    Score: 0.055
  35. Retinoblastoma protein expression and its predictors in triple-negative breast cancer. NPJ Breast Cancer. 2020; 6:19.
    View in: PubMed
    Score: 0.055
  36. Deep learning assessment of breast terminal duct lobular unit involution: Towards automated prediction of breast cancer risk. PLoS One. 2020; 15(4):e0231653.
    View in: PubMed
    Score: 0.054
  37. Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity. Mod Pathol. 2020 06; 33(6):1056-1064.
    View in: PubMed
    Score: 0.053
  38. Predictors of local recurrence following excision alone for ductal carcinoma in situ. Cancer. 1999 Jan 15; 85(2):427-31.
    View in: PubMed
    Score: 0.050
  39. Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS). JNCI Cancer Spectr. 2018 Nov; 2(4):pky063.
    View in: PubMed
    Score: 0.050
  40. Breast cancer risk factors in relation to estrogen receptor, progesterone receptor, insulin-like growth factor-1 receptor, and Ki67 expression in normal breast tissue. NPJ Breast Cancer. 2017; 3:39.
    View in: PubMed
    Score: 0.046
  41. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study. Breast Cancer Res Treat. 2017 Nov; 166(2):613-622.
    View in: PubMed
    Score: 0.045
  42. Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer. NPJ Breast Cancer. 2016; 2.
    View in: PubMed
    Score: 0.043
  43. A prospective study of endometriosis and risk of benign breast disease. Breast Cancer Res Treat. 2016 Oct; 159(3):545-52.
    View in: PubMed
    Score: 0.042
  44. Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses' Health Studies. Cancer Prev Res (Phila). 2016 Sep; 9(9):732-8.
    View in: PubMed
    Score: 0.042
  45. Postmenopausal mammographic breast density and subsequent breast cancer risk according to selected tissue markers. Br J Cancer. 2015 Sep 29; 113(7):1104-13.
    View in: PubMed
    Score: 0.039
  46. Intakes of fat and micronutrients between ages 13 and 18 years and the incidence of proliferative benign breast disease. Cancer Causes Control. 2015 Jan; 26(1):79-90.
    View in: PubMed
    Score: 0.037
  47. Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses' Health Study. Breast Cancer Res Treat. 2014 Oct; 147(3):639-51.
    View in: PubMed
    Score: 0.037
  48. Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk. J Natl Cancer Inst. 2013 Oct 16; 105(20):1571-8.
    View in: PubMed
    Score: 0.034
  49. Radial scars and subsequent breast cancer risk: results from the Nurses' Health Studies. Breast Cancer Res Treat. 2013 May; 139(1):277-85.
    View in: PubMed
    Score: 0.033
  50. Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers. Am J Surg Pathol. 2012 Oct; 36(10):1483-8.
    View in: PubMed
    Score: 0.032
  51. Adolescent intakes of vitamin D and calcium and incidence of proliferative benign breast disease. Breast Cancer Res Treat. 2012 Jul; 134(2):783-91.
    View in: PubMed
    Score: 0.031
  52. Intakes of alcohol and folate during adolescence and risk of proliferative benign breast disease. Pediatrics. 2012 May; 129(5):e1192-8.
    View in: PubMed
    Score: 0.031
  53. Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS. J Natl Cancer Inst. 2012 Apr 18; 104(8):614-21.
    View in: PubMed
    Score: 0.031
  54. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci U S A. 2011 Nov 08; 108(45):18378-83.
    View in: PubMed
    Score: 0.030
  55. Adolescent intakes of alcohol and folate and risk of proliferative benign breast disease. J Clin Oncol. 2011 Sep 20; 29(27_suppl):169.
    View in: PubMed
    Score: 0.030
  56. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst. 2011 Aug 03; 103(15):1179-89.
    View in: PubMed
    Score: 0.030
  57. Lifetime physical activity and the incidence of proliferative benign breast disease. Cancer Causes Control. 2011 Sep; 22(9):1297-305.
    View in: PubMed
    Score: 0.030
  58. COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat. 2011 Nov; 130(2):657-62.
    View in: PubMed
    Score: 0.030
  59. The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study. Breast Cancer Res Treat. 2011 Aug; 129(1):175-84.
    View in: PubMed
    Score: 0.029
  60. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 2011 Apr 01; 17(7):1867-74.
    View in: PubMed
    Score: 0.029
  61. DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. Clin Cancer Res. 2010 Dec 01; 16(23):5796-804.
    View in: PubMed
    Score: 0.028
  62. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res. 2010; 12(6):R95.
    View in: PubMed
    Score: 0.028
  63. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat. 2011 Feb; 126(1):185-92.
    View in: PubMed
    Score: 0.028
  64. Columnar cell lesions and subsequent breast cancer risk: a nested case-control study. Breast Cancer Res. 2010; 12(4):R61.
    View in: PubMed
    Score: 0.028
  65. Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. Am J Manag Care. 2010 May; 16(5):351-60.
    View in: PubMed
    Score: 0.027
  66. Intake of fiber and nuts during adolescence and incidence of proliferative benign breast disease. Cancer Causes Control. 2010 Jul; 21(7):1033-46.
    View in: PubMed
    Score: 0.027
  67. Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. Int J Cancer. 2010 Jan 01; 126(1):180-90.
    View in: PubMed
    Score: 0.027
  68. Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 2009; 11(6):R85.
    View in: PubMed
    Score: 0.026
  69. Determination of factors predicting for estrogen receptor positive (ER+) breast cancers in BRCA1 mutation carriers. J Clin Oncol. 2009 May 20; 27(15_suppl):11045.
    View in: PubMed
    Score: 0.026
  70. Adherence to long-term surveillance mammography among women with ductal carcinoma in situ treated with breast-conserving surgery. J Clin Oncol. 2009 Jul 01; 27(19):3211-6.
    View in: PubMed
    Score: 0.025
  71. Lobule type and subsequent breast cancer risk: results from the Nurses' Health Studies. Cancer. 2009 Apr 01; 115(7):1404-11.
    View in: PubMed
    Score: 0.025
  72. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res. 2008 Sep 01; 14(17):5357-67.
    View in: PubMed
    Score: 0.024
  73. Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet. 2007 Nov; 44(11):726-31.
    View in: PubMed
    Score: 0.022
  74. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). J Clin Oncol. 2006 Jun 20; 24(18_suppl):508.
    View in: PubMed
    Score: 0.021
  75. Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma. Cancer. 1998 Dec 15; 83(12):2502-8.
    View in: PubMed
    Score: 0.012
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.